Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.
In this year’s midterm election, voters in California approved Proposition 38, a $8.4 billion bond to fund immunology and immunotherapy research.
